Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam MAC vs Sevoflurane GA in TURB
NCT06217055Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of remimazolam in bladder cancer (2 arms), sponsored by Yonsei University. Primary endpoint: Anesthesia time excluding operation time. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06217055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217055.